Biotechnology News and Research

RSS

Clinical utility of Metabolon's Quantose IR test to be showcased at ADA meeting

Metabolon, Inc. announces that the clinical utility of the Company's lead diagnostic product Quantose IR will be featured in five poster presentations at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 8-12 in Philadelphia.

12 Jun 2012

ST Blood & Tissue Center, Saneron sign clinical supply and research collaboration agreement

Saneron CCEL Therapeutics, Inc. of Tampa, Florida, and South Texas Blood & Tissue Center of San Antonio, have signed a clinical supply and research collaboration agreement. Under the agreement, the South Texas Blood & Tissue Center will research approaches for recovering and processing proprietary mononuclear cells from umbilical cord blood.

12 Jun 2012

MVP receives European patent for PEG conjugates of interferon-beta-1b to treat MS

Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."

12 Jun 2012

BioMed Realty enters definitive agreement to acquire Granta Park

BioMed Realty Trust, Inc. today announced that it has entered into a definitive agreement to acquire Granta Park, comprising eleven laboratory and office buildings and a total of approximately 472,200 square feet of space, as well as approximately 138,400 square feet of development and expansion rights, in Cambridge, United Kingdom. The purchase price for the property is 126.8 million pounds, or approximately $196.0 million, excluding transaction costs.

11 Jun 2012

Scientists image structure of bacterium protein coat

Bacteria are omnipresent - in the water, the air and the soil, as well as in plants, animals and even people. We tend to think of bacteria as pathogenic, causing disease. We associate them with intestinal upsets and throat infections, pneumonia and blood poisoning.

11 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Cambridge facility to become worldwide hub for SAFC's chiral service

Sigma-Aldrich Corporation today announced that its custom manufacturing and services business unit, SAFC, will consolidate its global chiral chromatography screening and small scale purification operations and locate them at its Pharmorphix Solid State Research Laboratories in Cambridge, UK, to support its new integrated chiral chemistry offer.

11 Jun 2012

Positive results from Cara’s CR845 Phase II study on acute post-operative pain

Cara Therapeutics, Inc. today announced positive results from a Phase II study for the treatment of acute post-operative pain with its novel, peptide-based, peripherally-acting kappa opioid agonist, CR845.

11 Jun 2012

POI signs multi-year contract for DATATRAK ONE products

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced Pharm-Olam International (POI), a global Contract Research Organization (CRO), signed a multi-year, multi-million dollar contract standardizing on the cloud-based unified clinical research platform, DATATRAK ONE.

11 Jun 2012

New understanding about how placental growth is regulated before birth

Scientists at the Babraham Institute have gained a new understanding of how the growth of the placenta is regulated before birth, which has important implications for a healthy pregnancy.

11 Jun 2012

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Amgen today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis.

8 Jun 2012

Second-hand cigarette smoke linked with moderate to severe urinary disorders in children

According to the Environmental Protection Agency, parents are responsible for 90 percent of children's exposure to environmental (second-hand) tobacco smoke. Children with mothers who smoke are at even higher-risk for developing health disorders.

8 Jun 2012

Banyan, Amarantus complete collaboration agreement related to TBI development program

Amarantus BioSciences, Inc., a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.

8 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID lymphoma vaccine clinical trial.

8 Jun 2012

MGH, HSG to conduct PBT2 clinical trial in Huntington's disease

The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.

8 Jun 2012

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment of 40 patients in the second of three dose cohorts in Lm-LLO-E7-07, a randomized, single blind, placebo controlled Phase 2 dose escalation study assessing the safety and efficacy of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (CIN) 2/3.

7 Jun 2012

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the United States’ National Institutes of Health (NIH) has awarded a $6.4 million grant to Professor Mark Larché of McMaster University, Canada, to study mechanisms of tolerance developed by patients treated with Circassia’s Toleromune® allergy therapy.

7 Jun 2012

Study reviews role of gut microbes in nutrient absorption and energy regulation

Microorganisms in the human gastrointestinal tract form an intricate, living fabric made up of some 500 to 1000 distinct bacterial species, (in addition to other microbes). Recently, researchers have begun to untangle the subtle role these diverse life forms play in maintaining health and regulating weight.

7 Jun 2012

Biotechnology News and Research

Clinical utility of Metabolon's Quantose IR test to be showcased at ADA meeting

ST Blood & Tissue Center, Saneron sign clinical supply and research collaboration agreement

MVP receives European patent for PEG conjugates of interferon-beta-1b to treat MS

BioMed Realty enters definitive agreement to acquire Granta Park

Scientists image structure of bacterium protein coat

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Cambridge facility to become worldwide hub for SAFC's chiral service

Positive results from Cara’s CR845 Phase II study on acute post-operative pain

POI signs multi-year contract for DATATRAK ONE products

New understanding about how placental growth is regulated before birth

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Second-hand cigarette smoke linked with moderate to severe urinary disorders in children

Banyan, Amarantus complete collaboration agreement related to TBI development program

Strand, Trovagene enter MOU to license and validate HPV assay technology

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

MGH, HSG to conduct PBT2 clinical trial in Huntington's disease

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Study reviews role of gut microbes in nutrient absorption and energy regulation

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News